PetMed Express (PETS)
(Delayed Data from NSDQ)
$3.90 USD
+0.04 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.90 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.90 USD
+0.04 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.90 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth D Momentum B VGM
Zacks News
Surmodics (SRDX) Beats on Earnings in Q1, Guidance Solid
by Zacks Equity Research
Solid performance in the In Vitro Diagnostics segment drives Surmodics (SRDX) in first-quarter fiscal 2018.
Expedia (EXPE) Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Expedia's (EXPE) fourth-quarter results hurt by continuing investments in accelerated supply acquisition and cloud migration.
CVS Health (CVS) Q4 Earnings Beat Estimates, '18 View Upbeat
by Zacks Equity Research
A strong Pharmacy Services segment, benefiting from the upside in the specialty services Drives CVS Health's (CVS) topline in Q4.
Cardinal Health (CAH) Beats on Q2 Earnings, Raises '18 View
by Zacks Equity Research
Solid performance at the Medical Segment drove Cardinal Health (CAH) in Q2.
Nielsen (NLSN) Q4 Earnings Up Y/Y, Revenues Match Estimates
by Zacks Equity Research
Nielsen (NLSN) delivers strong fourth-quarter profits driven by strength in Watch segment. Weakness in the U.S. Buy segment continues to be a concern.
Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Lag
by Zacks Equity Research
Cardiovascular Systems (CSII) witnesses year-over-year increase in Q2 revenues on strength in both the segments.
STERIS (STE) Q3 Earnings Beat & Revenues Miss, Margins Up
by Zacks Equity Research
STERIS (STE) witnesses year-over-year rise in Q3 revenues on favorable underlying market trends along with new product and service offerings.
The Zacks Analyst Blog Highlights: Capital City Bank, HCA, MSCI, PetMed and Saia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Capital City Bank, HCA, MSCI, PetMed and Saia
Cerner (CERN) Misses Q4 Earnings Estimates, Bookings Soar
by Zacks Equity Research
Despite a decline in earnings year over year, all-time high bookings drive Cerner's (CERN) top line in Q4.
5 Top Stocks to Buy During This Bull & Bear Tug-of-War
by Tirthankar Chakraborty
While bullish investors show optimism on corporate earnings and prospects of tax cut, those with a bearish view fear that the Fed's embarking on a quicker route to interest rate hikes might derail the record bull run.
Haemonetics' (HAE) Q3 Earnings Top Estimates, EPS View Up
by Zacks Equity Research
Continued momentum in new business generation and geographical expansions drive Haemonetics (HAE) in the third quarter.
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q2
by Zacks Equity Research
Myriad Genetics' (MYGN) year over year decline in revenue was in Q2 is disappointing. However, strong demand for GeneSight tests was encouraging.
PetMed Express, Beazer Homes, Taylor Morrison, iRobot and NVIDIA as Zacks Bull and Bear of the Day
by Zacks Equity Research
PetMed Express, Beazer Homes, Taylor Morrison, iRobot and NVIDIA as Zacks Bull and Bear of the Day
Top Stock Picks for the Week of February 5th
by Brian Bolan
Two Stocks That Have Attractive Qualities for Investors.
LabCorp (LH) Q4 Earnings Beat Estimates, '18 View Promising
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development of late begins to gain traction from Chiltern acquisition, strong organic growth and a favorable foreign currency translation.
AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up
by Zacks Equity Research
Strong Growth in Pharmaceutical Distribution Segment and World Courier business drove AmerisourceBergen (ABC) in Q1.
Phibro Animal (PAHC) Beats on Q2 Earnings, Raises Guidance
by Zacks Equity Research
Phibro (PAHC) witnesses year-over-year improvement across all segments in Q2.
Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid
by Zacks Equity Research
Strong growth in BD Medical and BD Life sciences segments drove Becton, Dickinson's (BD) top line in Q1.
Top Ranked Growth Stocks to Buy for February 6th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 6th:
Bull Of The Day PetMed Express (PETS)
by Brian Bolan
A solid earnings report and a lawsuit dismissal could make the shorts turn tail on this stock.
athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4
by Zacks Equity Research
Strong growth in Business and Services segment drove athenahealth's (ATHN) top line in Q4.
Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q4
by Zacks Equity Research
Omnicell's (OMCL) year-over-year growth at both the segments in Q4 is encouraging.
ABIOMED (ABMD) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
ABIOMED (ABMD) rides high on record revenues from Impella in third-quarter fiscal 2018. The company is also well poised with new accomplishments.
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up
by Zacks Equity Research
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
Edwards Lifesciences (EW) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Edwards Lifesciences (EW) gains from strength in THVT on continued therapy adoption across all geographies in Q4.